A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Phase 1

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Placebo; Drug: RO5545965

• Registration Number: NCT02824055
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, three period crossover study to evaluate the effects of RO5545965 on the functioning of key brain circuitry involved in negative symptoms using functional magnetic resonance imaging (fMRI) and reward-based learning in stable participants with mild to moderate negative symptoms of schizophrenia treated with antipsychotics. Participants will be randomized to one of six different sequences during which each participant will receive three 3-week treatment courses with RO5545965 5 milligrams (mg), RO5545965 15 mg and placebo. Each treatment period will be separated by a washout period of 14 days. Total duration of study will be approximately 17 weeks.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-06-21
• Study Start: 2016-06-27
• Study First Submitted QC: 2016-07-01
• Study First Posted: 2016-07-06
• Primary Completion: 2017-04-24
• Study Completion: 2017-04-24
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-06
• Last Update Posted: 2017-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• A diagnostic and statistical manual of mental disorders-5 (DSM-5) diagnosis of schizophrenia as established by structured clinical interview for DSM-5-clinical trial (SCID-5-CT) at screening
• Participants with no hospitalization for worsening of schizophrenia within 3 months prior to screening
• Male and female participants with no childbearing capacity; females must be either surgically sterile or postmenopausal for at least 1 year
• Body mass index (BMI) greater than (>) 18.5 kilograms per square meter (kg/m^2) and less than (<) 35 kg/m^2
• Fluent in English, even if English is not the primary language
• Participants with clinical global impression-severity (CGI-S) score greater than or equal to (>/=) 3 (mildly ill)
• Participants with a score of less than or equal to (</=) 4 (moderate) on positive and negative syndrome scale (PANSS) items P7 (hostility), G8 (uncooperativeness) and G6 (depression)
• Participants with PANSS negative symptom factor score >/=18
• Participants with calgary depression rating scale for schizophrenia (CDSS) score </=8
• Participants on stable treatment, that is 6 weeks without change, with no more than two antipsychotics prior to screening

Read More

Exclusion Criteria

• Moderate to severe substance use disorder within 6 months as defined by DSM-5
• Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenorphine, methadone, cannabinoids, cocaine and barbiturates
• Participants at significant risk of suicide or harming him or herself or others according to the Investigator's judgment
• History of neuroleptic malignant syndrome
• A prior or current general medical condition that might be impairing cognition or other psychiatric functioning
• A movement disorder due to antipsychotic treatment not currently controlled with anti-extrapyramidal symptoms (anti-EPS) treatment or another movement disorder which might affect the ratings on the EPS scales
• Participants with a score >2 (mild) in any of the four CGI-S items of the extrapyramidal symptom rating scale (ESRS-A)
• History of human immunodeficiency virus (HIV) infection, Hepatitis B, or Hepatitis C infection
• QTcF interval >450 milliseconds (msec) (470 msec for females) or other significant abnormality on screening electrocardiogram (ECG) based on centralized reading
• Clinically significant abnormalities in laboratory safety test results
• Significant or unstable physical condition
• Receipt of an investigational drug within 90 days or 5 times the half-life of the investigational drug, whatever is longer, prior to screening
• Previously received RO5545965
• Electroconvulsive treatment (ECT) within 6 months prior to screening
• Current or 6 months prior to screening treatment with olanzapine or clozapine
• Change in benzodiazepine or sleep medication regimen within 2 weeks prior to screening
• Change in anti-EPS medication within two weeks prior to screening
• Use of prohibited medications taken within 14 days or within 5 times the elimination half-life of the medication before the first study drug administration
• Use of any strong or moderate inhibitor of cytochrome P 450 3A (CYP3A) or CYP2C8 and any inducer of CYP3A within 14 days or within 5 times the elimination half-life of the medication (whichever is longer) before the first study drug administration
• Use of any other nutrients known to modulate CYP3A activity within 1 week before the first study drug administration

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo first; then RO5545965 15 mg; then RO5545965 5mg	Placebo	Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
Placebo first; then RO5545965 15 mg; then RO5545965 5mg	RO5545965	Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
Placebo first; then RO5545965 5 mg; then RO5545965 15 mg	Placebo	Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
Placebo first; then RO5545965 5 mg; then RO5545965 15 mg	RO5545965	Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 15 mg first; then Placebo; then RO5545965 5 mg	Placebo	Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 15 mg first; then Placebo; then RO5545965 5 mg	RO5545965	Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 15 mg first; then RO5545965 5 mg; then Placebo	Placebo	Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 15 mg first; then RO5545965 5 mg; then Placebo	RO5545965	Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 5 mg first; then Placebo; then RO5545965 15 mg	Placebo	Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 5 mg first; then Placebo; then RO5545965 15 mg	RO5545965	Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 5 mg first; then RO5545965 15 mg; then Placebo	Placebo	Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
RO5545965 5 mg first; then RO5545965 15 mg; then Placebo	RO5545965	Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.

Primary Outcome Measures

Name	Time	Method
Activity of the ventral striatum during reward expectation in a monetary incentive delay fMRI task as measured by blood oxygen level dependent (BOLD) activity	Baseline (Day 1) up to end of study (up to 17 weeks)
Performance in reward based learning tasks as measured by the working memory reinforcement learning task	Day 22 up to Day 92
Apparent volume of distribution (Vz/F)	Pre-dose on Days 8, 15, 22, 43, 50, 57, 78, 85 and 96; additional 2 hour post-dose on Days 15, 50, and 85
Performance in reward based learning tasks as measured by the effort cost/benefit tradeoff task	Day 22 up to Day 92
Apparent oral clearance (CL/F)	Pre-dose on Days 8, 15, 22, 43, 50, 57, 78, 85 and 96; additional 2 hour post-dose on Days 15, 50, and 85

Secondary Outcome Measures

Name	Time	Method
Cerebral blood flow in key brain areas (ventral striatum, orbitofrontal cortex) implicated in the etiology of negative symptoms as measured by arterial spin labeling (ASL)	Baseline (Day 1) up to end of study (up to 17 weeks)
Overall global impression of negative symptoms based on CGI-I negative symptoms	Baseline (Day 1), Days 22, 57, and 92
Symptom domains of schizophrenia based on PANSS factor subscales	Baseline (Day 1), Days 22, 57, and 92
Overall clinical status based on CGI-S scores	Baseline (Day 1), Days 22, 57, and 92
Overall clinical status based on CGI-Improvement (CGI-I) score	Baseline (Day 1), Days 22, 57, and 92
Overall global impression of negative symptoms based on CGI-S negative symptoms	Baseline (Day 1), Days 22, 57, and 92
Activity in the dorsolateral prefrontal cortex in the N-back working memory task as measured by BOLD activity	Baseline (Day 1) up to end of study (up to 17 weeks)
Overall symptoms score of schizophrenia based on total PANSS	Baseline (Day 1), Days 22, 57, and 92
Negative symptoms score of schizophrenia based on brief negative symptom scale (BNSS)	Baseline (Day 1), Days 22, 57, and 92
Area under the concentration-time curve (AUC)	Pre-dose on Days 8, 15, 22, 43, 50, 57, 78, 85 and 96; additional 2 hour post-dose on Days 15, 50, and 85
Maximum observed plasma concentration (Cmax)	Pre-dose on Days 8, 15, 22, 43, 50, 57, 78, 85 and 96; additional 2 hour post-dose on Days 15, 50, and 85
Number of participants with adverse events (AEs) and serious adverse events (SAEs)	Screening (Day -15 to Day -1) up to end of study (up to 17 weeks)

Trial Locations

Locations (3)

CNS Network; 🇺🇸 Garden Grove, California, United States

St Louis Clinical Trials; 🇺🇸 Saint Louis, Missouri, United States

Parexel California Clinical Trials Medical Group; 🇺🇸 Glendale, California, United States